KatherineWesseling(Wesseling)PerryMDMSCR

PubMed

• 27 citations
  Use of Denosumab in Children With Osteoclast Bone Dysplasias: Report of Three Cases.
  Alexander Upfill-Brown, Susan V. Bukata, Nicholas M. Bernthal, Alan L Felsenfeld, Scott D. Nelson
  JBMR Plus. 2019-08-22
• 23 citations
  Osteocyte Protein Expression Is Altered in Low-Turnover Osteoporosis Caused by Mutations in WNT1 and PLS3.
  Katherine Wesseling-Perry, Riikka E. Mäkitie, Ville-Valtteri Välimäki, Tero Laine, Christine M. Laine
  The Journal of Clinical Endocrinology and Metabolism. 2017-07-01
• 53 citations
  Chronic kidney disease mineral and bone disorder in children
  Katherine Wesseling, Sevcan A. Bakkaloglu, Isidro B. Salusky
  Pediatric Nephrology. 2008-02-01

Journal Articles

• Chronic kidney disease: mineral and bone disorder in children  
  Wesseling-Perry K and Salusky IB, Semin Nephrol, 1/1/2013
• Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children  
  Wesseling-Perry K, Salusky IB, Pediatr Nephrol, 1/1/2013
• Bone biopsy in renal osteodystrophy: continued insights into a complex disease  
  Christov M, Pereira R, Wesseling-Perry K, Curr Opin Nephrol Hypertens, 1/1/2013
• Short daily hemodialysis is associated with lower plasma FGF23 levels when compared with conventional hemodialysis  
  Zaritsky J, Rastogi A, Fischmann G, Yan J, Kleinman K, Chow G, Gales B, Salusky IB, Wesseling-Perry K, Nephrol Dial Transplant, 1/1/2013
• FGF23 and mineral metabolism in the early post-renal transplantation period  
  Wesseling-Perry K, Pereira RC, Tsai E, Ettenger R, Juppner H, Salusky IB, Pediatr Neprhol, 1/1/2013
• The skeletal consequences of growth hormone therapy in dialyzed children: a randomized trial  
  Bacchetta J, Wesseling-Perry K , Kuizon B, Pereira RC, Gales B, Wang H, Elashoff R, Salusky IB, Clinical Journal of the American Society of Nephrology, 1/1/2013
• FGF23 inhibits extra-renal synthesis of 1,25-diydroxyvitamin D in human monocytes  
  Bacchetta J, Sea JL, Chun RF, Lisse TS, Wesseling-Perry K, Gales B, Adams JS, Salusky IB, Hewison M, J Bone Miner Res, 1/1/2013
• Idiopathic juvenile osteoporosis: a cross-sectional single-centre experience with bone histomorphometry and quantitative computed tomography  
  Bacchetta J, Wesseling-Perry K, Gilsanz V, Gales B, Pereira RC, Salusky IB, Pediatr Rheumatol Online J, 1/1/2013
• The osteocyte in CKD: new concepts regarding the role of FGF23 in mineral metabolism and systemic complications  
  Wesseling-Perry K and Juppner H, Bone, 1/1/2012
• Bone disease in pediatric chronic kidney disease  
  Wesseling-Perry K, Pediatric Nephrology, 1/1/2012
• The consequences of chronic kidney disease on bone metabolism and growth in children  
  Bacchetta J, Harambat J, Cochat P, Salusky IB, Wesseling-Perry K, Nephrol Dial Transplant, 1/1/2012
• Early Skeletal and Biochemical Alterations in Pediatric Chronic Kidney Disease  
  Wesseling-Perry K, Pereira RC, Tseng CH, Elashoff R, Zaritsky JJ, Yadin O, Sahney S, Gales B, Juppner H, Salusky IB, Clinical Journal of the American Society of Nephrology, 1/1/2012
• Uric acid and IGF1 as potential determinants of FGF23 metabolism in children with normal renal function  
  Bacchetta J, Cochat P, Salusky IB, Wesseling-Perry K, Pediatric Nephrology, 1/1/2012
• FGF-23: Is It Ready for Prime-Time?  
  Wesseling-Perry K, Clin Chem, 1/1/2011
• CKD-MBD after kidney transplantation  
  Wesseling-Perry K, Bacchetta J, Pediatric Nephrology, 1/1/2011
• Mineral abnormalities and long-term graft function in pediatric renal transplant recipients: a role for FGF-23?  
  Wesseling-Perry K, Tsai EW, Ettenger RB, Juppner H, and Salusky IB, Nephrology, Dialysis, Transplantation, 1/1/2011
• Racial differences in correlations between reported dietary intakes of carotenoids and their concentration biomarkers  
  Arab L, Cambou MC, Craft N, Wesseling-Perry K, Jardack P, Ang A, American Journal of Clinical Nutrition, 1/1/2011
• Calcitriol and Doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hy...  
  Wesseling-Perry K, Pereira RC, Sahney S, Gales B, Wang H, Elashoff R, Juppner H, and Salusky IB, Kidney International, 1/1/2011
• Value of the New Bone Classification System in Pediatric Renal Osteodystrophy  
  Bakkaloglu S, Wesseling-Perry K, Pereira R, Gales B, Wang H, Elashoff R, and Salusky IB, Clinical Journal of the American Society of Nephrology, 10/5/2010
• Eight self-administered 24-hour dietary recalls using the internet are feasible in African-Americans and Whites: the energetics study  
  Arab L, Wesseling-Perry K, Jardack P, Henry J, Winter A, Journal of the American Dietetic Association, 6/1/2010
• The calcemic response to continuous PTH infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH(7-84)  
  Wesseling-Perry K, Harkins GC, Wang H, Elashoff R, Gales B, Horwitz MJ, Stewart AF, Juppner H, and Salusky IB, Journal of Clinical Endocrinology and Metabolism, 6/1/2010
• Circulating fibroblast growth factor 23 in patients with end-stage renal disease by peritoneal dialysis is intact and biologically active  
  Shimada T, Urakawa I, Isakova T, Yamazaki Y, Epstein M, Wesseling-Perry K, Wolf M, Salusky IB, and Juppner H, Journal of Clinical Endocrinology and Metabolism, 2/1/2010
• FGF-23 in Bone Biology  
  Wesseling-Perry K, Pediatric Nephrology, 1/1/2010
• Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease  
  Pereira RC, Juppner H, Yadin O, Salusky IB, and Wesseling-Perry K, Bone, 12/1/2009
• Is replacement therapy with nutritional and active forms of vitamin D required in Chronic Kidney Disease Mineral and Bone Disorder?  
  Wesseling-Perry K and Salusky IB, Current Opinion in Nephrology and Hypertension, 7/1/2009
• Join now to see all